Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development. Justification of dissolution specifications and establishment of dissolution safe space is an important application of such modeling approaches. In case of molecules exhibiting saturable absorption behavior, justification of dissolution specifications requires development of a model that incorporates effects of transporters is critical to simulate in vivo scenario. In the present case, we have developed a semi-mechanistic PBBM to describe the non-linearity of BCS class III molecule metformin for justification of dissolution specifications of extended release formulation at strengths 500 mg and 1000 mg. Semi-mechanistic PBBM was built using physicochemical properties, dissolution and non-linearity was accounted through incorporation of multiple transporter kinetics at absorption level. The model was extensively validated using literature reported intravenous, oral (immediate & extended release) formulations and further validated using in-house bioequivalence data in fasting and fed conditions. Virtual dissolution profiles at lower and upper specifications were generated to justify the dissolution specifications. The model predicted literature as well as in-house clinical study data with acceptable prediction errors. Further, virtual bioequivalence trials predicted the bioequivalence outcome that matched with clinical study data. The model predicted bioequivalence when lower and upper specifications were compared against pivotal test formulations thereby justifying dissolution specifications. Overall, complex and saturable absorption pathway of metformin was successfully simulated and this work resulted in regulatory acceptance of dissolution specifications which has ability to reduce multiple dissolution testing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1208/s12249-024-02904-9 | DOI Listing |
Drug Deliv Transl Res
January 2025
Leicester Institute of Pharmaceutical, Health and Social Care Innovations, Leicester School of Pharmacy, De Montfort University, Leicester, LE1 9BH, UK.
The use of dissolving microneedle arrays (dMNA) for intradermal and transdermal drug delivery has been a growing trend in the field for the past decades. However, a lack of specific regulatory standards still hinders their clinical development and translation to market. It is also well-known that dMNA composition significantly impacts their performance, with each new formulation potentially presenting a challenge for developers, manufacturers and regulatory agencies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Queen Mary University of London, London, United Kingdom.
Background: Research has demonstrated that spousal loss through widowhood or divorce are associated with an increased risk of dementia and deteriorated cognitive performance. This is likely due to high levels of stress characteristic of these life events. Evidence suggests that neuropathology typically seen in Alzheimer's disease, for example, β-amyloid (Aβ), may be a by-product of chronic stress.
View Article and Find Full Text PDFColloids Surf B Biointerfaces
December 2024
Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Lab of Colloid, Interface and Chemical Thermodynamics, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address:
Significant progress has been achieved with diversity of short peptide supramolecular assemblies. However, their programmable phase modulation by single stimulus remains a great challenge. Herein, we demonstrate a dipeptide supramolecular system undergoes sequentially coupled phase transitions upon hydrogen bonding association and dissociation triggered by a single fatty acid.
View Article and Find Full Text PDFJ Colloid Interface Sci
December 2024
School of Environmental and Materials Engineering, Yantai University, Yantai 264005, China. Electronic address:
J Pharm Sci
December 2024
Janssen Research & Development, LLC, Discovery Pharmaceutics, San Diego, CA, USA.
Rat pharmacokinetic studies are commonly utilized in early discovery to support absorption, distribution, metabolism, and excretion optimization of active pharmaceutical ingredients (APIs). The aim of this work was to compare exposures from fit-for-purpose oral suspension and solution formulations in rats to guidance provided by the refined Developability Classification System (rDCS) with respect to identifying potential limits to oral absorption, formulation strategy selection, and to optimize oral bioavailability (BA). This investigation utilized six diverse APIs covering a large range of biorelevant solubility, metabolic stability, and oral BA in rats.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!